Collagen/therapeutic use; Fatty Acids/therapeutic use; Flavonoids/therapeutic use; Health Food; Humans; Nutrition Therapy; Osteoarthritis/therapy; Phenols/therapeutic use; Phytosterols/therapeutic use; Vitamin D/therapeutic use
Abstract :
[en] OBJECTIVES: The aim of this first global systematic review on selected nutraceuticals was to synthesize and evaluate scientific relevant data available in the literature. Evidences that can support health, physiological or functional benefit on osteoarthritis (OA) were gathered and the level of evidence relative to each of these ingredients was highlighted. METHODOLOGY: Relevant scientific data (positive or not) regarding OA were searched for five groups of compounds (avocado/soybean unsaponifiables (ASU), n-3 polyunsaturated fatty acids, collagen hydrosylates (CHs), vitamin D, polyphenols) within preclinical (in vitro and in vivo), epidemiological, and clinical studies. The following criteria were evaluated to assess the methodology quality of each study: (1) study question; (2) study population; (3) primary endpoint; (4) study design (randomization, control, blinding, duration of follow up); (5) data analysis and interpretation. A scientific consensus was determined for all studied nutraceuticals to evaluate their efficacy in OA. RESULTS: The studied compounds demonstrated different potencies in preclinical studies. Most of them have demonstrated anti-catabolic and anti-inflammatory effects by various inhibitory activities on different mediators. Vitamin D showed a pro-catabolic effect in vitro and the polyphenol, Genistein, had only anti-inflammatory potency. The evaluation of the clinical data showed that ASU was the only one of the studied ingredients to present a good evidence of efficacy, but the efficient formulation was considered as a drug in some countries. Pycnogenol showed moderate evidence of efficacy, and vitamin D and collagen hydrolysate demonstrated a suggestive evidence of efficacy, whereas curcumin, epigallocatechin-3-gallate (EGCG) and resveratrol had only preclinical evidence of efficacy due to the lack of clinical data. The literature gathered for n-3 PUFA, nobiletin and genistein was insufficient to conclude for their efficacy in OA. CONCLUSION: Additional data are needed for most of the studied nutraceuticals. Studies of good quality are needed to draw solid conclusions regarding their efficacy but nutraceuticals could represent good alternates for OA management. Their use should be driven by any recommendations.
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Lambert, Cécile ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Couchourel, D.
Ripoll, C.
Chiotelli, E.
Language :
English
Title :
Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products.
Publication date :
2011
Journal title :
Osteoarthritis and Cartilage
ISSN :
1063-4584
eISSN :
1522-9653
Publisher :
Elsevier, United Kingdom
Volume :
19
Issue :
1
Pages :
1-21
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
American College of Rheumatology Subcommittee on Osteoarthritis G Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-1915.
Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through. Osteoarthritis Cartilage 2010, 18(4):476-499.
Ameye L.G., Chee W.S. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 2006, 8. R127.
Kalra E.K. Nutraceutical-definition and introduction. AAPS PharmSci 2003, 5. E25.
Hochberg M.C., Clegg D.O. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage 2008, 16(Suppl 3):S22-S24.
Lee Y.H., Woo J.H., Choi S.J., Ji J.D., Song G.G. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010, 30:357-363.
Vangsness C.T., Spiker W., Erickson J. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis. Arthroscopy 2009, 25:86-94.
Huskisson E.C. Glucosamine and chondroitin for osteoarthritis. J Int Med Res 2008, 36:1161-1179.
Scarpellini M., Lurati A., Vignati G., Marrazza M.G., Telese F., Re K., et al. Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the " Magenta osteoarthritis study" J Orthop Traumatol 2008, 9:81-87.
Sawitzke A.D., Shi H., Finco M.F., Dunlop D.D., Bingham C.O., Harris C.L., et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008, 58:3183-3191.
Bornhoft G., Maxion-Bergemann S., Wolf U., Kienle G.S., Michalsen A., Vollmar H.C., et al. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol 2006, 6:56.
Schneeman B. FDA's review of scientific evidence for health claims. J Nutr 2007, 137:493-494.
Calder P.C., Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors 2009, 35:266-272.
Darlington L.G., Stone T.W. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr 2001, 85:251-269.
Curtis C.L., Hughes C.E., Flannery C.R., Little C.B., Harwood J.L., Caterson B. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem 2000, 275:721-724.
Curtis C.L., Rees S.G., Cramp J., Flannery C.R., Hughes C.E., Little C.B., et al. Effects of n-3 fatty acids on cartilage metabolism. Proc Nutr Soc 2002, 61:381-389.
Curtis C.L., Rees S.G., Little C.B., Flannery C.R., Hughes C.E., Wilson C., et al. Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum 2002, 46:1544-1553.
Zainal Z., Longman A.J., Hurst S., Duggan K., Caterson B., Hughes C.E., et al. Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis. Osteoarthritis Cartilage 2009, 17:896-905.
Lippiello L., Fienhold M., Grandjean C. Metabolic and ultrastructural changes in articular cartilage of rats fed dietary supplements of omega-3 fatty acids. Arthritis Rheum 1990, 33:1029-1036.
Roush J.K., Dodd C.E., Fritsch D.A., Allen T.A., Jewell D.E., Schoenherr W.D., et al. Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. J Am Vet Med Assoc 2010, 236:59-66.
Wang Y., Wluka A.E., Hodge A.M., English D.R., Giles G.G., O'Sullivan R., et al. Effect of fatty acids on bone marrow lesions and knee cartilage in healthy, middle-aged subjects without clinical knee osteoarthritis. Osteoarthritis Cartilage 2008, 16:579-583.
Stammers T., Sibbald B., Freeling P. Efficacy of cod liver oil as an adjunct to non-steroidal anti-inflammatory drug treatment in the management of osteoarthritis in general practice. Ann Rheum Dis 1992, 51:128-129.
Cho S.H., Jung Y.B., Seong S.C., Park H.B., Byun K.Y., Lee D.C., et al. Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Eur Ann Allergy Clin Immunol 2003, 35:212-216.
Cake M.A., Read R.A., Guillou B., Ghosh P. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cartilage 2000, 8:404-411.
Boileau C., Martel-Pelletier J., Caron C., Cheng S., Msika P., Guillou G.B., et al. Protective effects of total fraction of avocado/soybean unsaponifiables (ASU) on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and MMP-13. Arthritis Res Ther 2009, 11. R41 doi:10.1186/ar2649.
Msika P., Baudouin C., Saunois A., Bauer T. Avocado/soybean unsaponifiables, ASU EXPANSCIENCEtrade mark, are strictly different from the nutraceutical products claiming ASU appellation. Osteoarthritis Cartilage 2008, 16(10):1275-1276.
Henrotin Y. Avocado/soybean unsaponifiable (ASU) to treat osteoarthritis: a clarification. Osteoarthritis Cartilage 2008, 16:1118-1119. author reply 1120.
Lippiello L., Nardo J.V., Harlan R., Chiou T. Metabolic effects of avocado/soy unsaponifiables on articular chondrocytes. Evid Based Complement Alternat Med 2008, 5:191-197.
Mauviel A., Daireaux M., Hartmann D.J., Galera P., Loyau G., Pujol J.P. Effects of unsaponifiable extracts of avocado/soy beans (PIAS) on the production of collagen by cultures of synoviocytes, articular chondrocytes and skin fibroblasts. Rev Rhum Mal Osteoartic 1989, 56:207-211.
Mauviel A., Loyau G., Pujol J.P. Effect of unsaponifiable extracts of avocado and soybean (Piascledine) on the collagenolytic action of cultures of human rheumatoid synoviocytes and rabbit articular chondrocytes treated with interleukin-1. Rev Rhum Mal Osteoartic 1991, 58:241-245.
Henrotin Y., Labasse A., Jaspar J.M., De Groote D., Zheng S.X., Guillou B., et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol 1998, 17:31-39.
Henrotin Y.E., Sanchez C., Deberg M.A., Piccardi N., Guillou G.B., Msika P., et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003, 30:1825-1834.
Gabay O., Gosset M., Levy A., Salvat C., Sanchez C., Pigenet A., et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis Cartilage 2008, 16:373-384.
Au R.Y., Al-Talib T.K., Au A.Y., Phan P.V., Frondoza C.G. Avocado soybean unsaponifiables (ASU) suppress TNF-alpha, IL-1beta, COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. Osteoarthritis Cartilage 2007, 15:1249-1255.
Boumediene K., Felisaz N., Bogdanowicz P., Galera P., Guillou G.B., Pujol J.P. Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta1 and beta2 in cultured articular chondrocytes. Arthritis Rheum 1999, 42:148-156.
Henrotin Y.E., Deberg M.A., Crielaard J.M., Piccardi N., Msika P., Sanchez C. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. J Rheumatol 2006, 33:1668-1778.
Kawcak C.E., Frisbie D.D., McIlwraith C.W., Werpy N.M., Park R.D. Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res 2007, 68:598-604.
Altinel L., Saritas Z.K., Kose K.C., Pamuk K., Aksoy Y., Serteser M. Treatment with unsaponifiable extracts of avocado and soybean increases TGF-beta1 and TGF-beta2 levels in canine joint fluid. Tohoku J Exp Med 2007, 211:181-186.
Lequesne M., Maheu E., Cadet C., Dreiser R.L. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002, 47:50-58.
Maheu E., Mazieres B., Valat J.P., Loyau G., Le Loet X., Bourgeois P., et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998, 41:81-91.
Blotman F., Maheu E., Wulwik A., Caspard H., Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 1997, 64:825-834.
Christensen R., Bartels E.M., Astrup A., Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008, 16:399-408.
Walrand S., Chiotelli E., Noirt F., Mwewa S., Lassel T. Consumption of a functional fermented milk containing collagen hydrolysate improves the concentration of collagen-specific amino acids in plasma. J Agric Food Chem 2008, 56:7790-7795.
Bello A.E., Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr Med Res Opin 2006, 22:2221-2232.
Oesser S., Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res 2003, 311:393-399.
Schunck M., Schulze C.H., Oesser S. disparate efficacy of collagen hydrolysate and glucosamine on the extracellular matrix metabolism of articular chondrocytes. OA and Cartilage 2006, 14:S114. (Abstract).
Oesser S., Proksch E., Schunck M. prophylactic treatment with a special collagen hydrosylate decreases cartilage tissue degeneration in the knee joints. OA and Cartilage 2008, 16:S45. (Abstract).
Nakatani S., Mano H., Sampei C., Shimizu J., Wada M. Chondroprotective effect of the bioactive peptide prolyl-hydroxyproline in mouse articular cartilage in vitro and in vivo. Osteoarthritis Cartilage 2009, 17:1620-1627.
Clark K.L., Sebastianelli W., Flechsenhar K.R., Aukermann D.F., Meza F., Millard R.L., et al. 24-week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Curr Med Res Opin 2008, 24:1485-1496.
Zuckley L., Angelopoulou K., Carpenter M.S.S., Meredith B.A., Kline G., Rowinski M., et al. Collagen hydrosylate improves joint function in adults with mild symptoms of osteoarthritis of the knee. Medecine & Science in Sports & Excercise 2004, 36:S153-S154.
Moskowitz R.W. Role of collagen hydrolysate in bone and joint disease. Semin Arthritis Rheum 2000, 30:87-99.
Benito-Ruiz P., Camacho-Zambrano M.M., Carrillo-Arcentales J.N., Mestanza-Peralta M.A., Vallejo-Flores C.A., Vargas-Lopez S.V., et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr 2009, 60(Suppl 2):99-113.
McAlindon T.E., Felson D.T., Zhang Y., Hannan M.T., Aliabadi P., Weissman B., et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996, 125:353-359.
Radin E.L., Rose R.M. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 1986, 213:34-40.
Cantatore F.P., Corrado A., Grano M., Quarta L., Colucci S., Melillo N. Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Clin Rheumatol 2004, 23:490-495.
Goldring M.B., Goldring S.R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010, 1192:230-237.
Martel-Pelletier J., Pelletier J.P. Is osteoarthritis a disease involving only cartilage or other articular tissues?. Eklem Hastalik Cerrahisi 2010, 21:2-14.
Bergink A.P., Uitterlinden A.G., Van Leeuwen J.P., Buurman C.J., Hofman A., Verhaar J.A., et al. Vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee: the Rotterdam Study. J Clin Rheumatol 2009, 15:230-237.
Breijawi N., Eckardt A., Pitton M.B., Hoelzl A.J., Giesa M., von Stechow D., et al. Bone mineral density and vitamin D status in female and male patients with osteoarthritis of the knee or hip. Eur Surg Res 2009, 42:1-10.
Tetlow L.C., Woolley D.E. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage 2001, 9:423-431.
Tetlow L.C., Woolley D.E. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1999, 1:63-70.
Jefferies D., Farquharson C., Thomson J., Smith W., Seawright E., McCormack H., et al. Differences in metabolic parameters and gene expression related to osteochondrosis/osteoarthrosis in pigs fed 25-hydroxyvitamin D3. Vet Res 2002, 33:383-396.
Lane N.E., Gore L.R., Cummings S.R., Hochberg M.C., Scott J.C., Williams E.N., et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum 1999, 42:854-860.
Felson D.T., Niu J., Clancy M., Aliabadi P., Sack B., Guermazi A., et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum 2007, 56:129-136.
Ding C., Parameswaran V., Burgess J., Cicuttini F., Jones G. Serum level of vitamin d, winter sun exposure knee radiographic osteoarthritis and knee cartilage loss in older adults: the Tasmania Older Adult Cohort (TASOAC) Study. OA and Cartilage 2008, 16:S147. (Abstract).
Javaid M., Tolskykh I., Neogi T., Guermazi A., Curtis J., Torner J., et al. Non-linear association between baseline serum 25(OH) vitamin d concentration and incident radiographic knee OA: the MOST Study. OA and Cartilage 2008, 16:S150. (Abstract).
Cisar P., Jany R., Waczulikova I., Sumegova K., Muchova J., Vojtassak J., et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res 2008, 22:1087-1092.
Grimm T., Schafer A., Hogger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 2004, 36:811-822.
Farid R., Mirfeizi Z., Mirheidari M., Rezaieyazdi Z., Mansouri H., Esmaelli H., et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutrition Research 2007, 27:692-697.
Belcaro G., Cesarone M.R., Errichi S., Zulli C., Errichi B.M., Vinciguerra G., et al. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep 2008, 13:271-276.
Belcaro G., Cesarone M.R., Errichi S., Zulli C., Errichi B.M., Vinciguerra G., et al. Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res 2008, 22:518-523.
Imada K., Lin N., Liu C., Lu A., Chen W., Yano M., et al. Nobiletin, a citrus polymethoxy flavonoid, suppresses gene expression and production of aggrecanases-1 and -2 in collagen-induced arthritic mice. Biochem Biophys Res Commun 2008, 373:181-185.
Ishiwa J., Sato T., Mimaki Y., Sashida Y., Yano M., Ito A. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol 2000, 27:20-25.
Lin N., Sato T., Takayama Y., Mimaki Y., Sashida Y., Yano M., et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 2003, 65:2065-2071.
Henrotin Y., Clutterbuck A.L., Allaway D., Lodwig E.M., Harris P., Mathy-Hartert M., et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage 2010, 18:141-149.
Liacini A., Sylvester J., Li W.Q., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003, 288:208-217.
Schulze-Tanzil G., Mobasheri A., Sendzik J., John T., Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 2004, 1030:578-586.
Shakibaei M., John T., Schulze-Tanzil G., Lehmann I., Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445.
Shakibaei M., Schulze-Tanzil G., John T., Mobasheri A. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. Ann Anat 2005, 187:487-497.
Toegel S., Wu S.Q., Piana C., Unger F.M., Wirth M., Goldring M.B., et al. Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage 2008, 16:1205-1212.
Williamson S.M., Mobasheri A., Vaughan-Thomas A., Thompson N.J., Shakibaei M. Curcumin and resveratrol reduce lipopolysaccharide mediated glycosaminoglycan release in an explant model of canine articular cartilage. OA and Cartilage 2006, 14:S102. (Abstract).
Clutterbuck A.L., Mobasheri A., Shakibaei M., Allaway D., Harris P. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann N Y Acad Sci 2009, 1171:428-435.
Mathy M., Sanchez C., Priem F., Henrotin Y. Curcumin inhibits interleukin-6, -8, nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. OA and Cartilage 2007, 15:C115. (Abstract).
Clutterbuck A.L., Mobasheri A., Rogers T.C., Wiseman J., Allaway D., Harris P. Curcumin (diferuloylmethane) blocks il-1 beta stimulated glycosaminoglycan and prostaglandin e2 release from cartilage explants in an in vitro model of osteoarthritis. OA and Cartilage 2008, 16:S221. (Abstract).
Mathy-Hartert M., Jacquemond-Collet I., Priem F., Sanchez C., Lambert C., Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 2009, 58:899-908.
Chowdhury T.T., Salter D.M., Bader D.L., Lee D.A. Signal transduction pathways involving p38 MAPK, JNK, NFkappaB and AP-1 influences the response of chondrocytes cultured in agarose constructs to IL-1beta and dynamic compression. Inflamm Res 2008, 57:306-313.
Lev-Ari S., Strier L., Kazanov D., Elkayam O., Lichtenberg D., Caspi D., et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 2006, 45:171-177.
Kulkarni R.R., Patki P.S., Jog V.P., Gandage S.G., Patwardhan B. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991, 33:91-95.
Claassen H., Briese V., Manapov F., Nebe B., Schunke M., Kurz B. The phytoestrogens daidzein and genistein enhance the insulin-stimulated sulfate uptake in articular chondrocytes. Cell Tissue Res 2008, 333:71-79.
Hooshmand S., Soung do Y., Lucas E.A., Madihally S.V., Levenson C.W., Arjmandi B.H. Genistein reduces the production of proinflammatory molecules in human chondrocytes. J Nutr Biochem 2007, 18:609-614.
Ham K.D., Oegema T.R., Loeser R.F., Carlson C.S. Effects of long-term estrogen replacement therapy on articular cartilage IGFBP-2, IGFBP-3, collagen and proteoglycan levels in ovariectomized cynomolgus monkeys. Osteoarthritis Cartilage 2004, 12:160-168.
Ahmed S., Rahman A., Hasnain A., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002, 33:1097-1105.
Singh R., Ahmed S., Islam N., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002, 46:2079-2086.
Singh R., Ahmed S., Malemud C.J., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res 2003, 21:102-109.
Tokuda H., Takai S., Hanai Y., Matsushima-Nishiwaki R., Yamauchi J., Harada A., et al. (-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-stimulated interleukin-6 synthesis in osteoblasts. Horm Metab Res 2008, 40:674-678.
Huang G.S., Tseng C.Y., Lee C.H., Su S.L., Lee H.S. Effects of (-)-epigallocatechin-3-gallate on cyclooxygenase 2, PGE(2), and IL-8 expression induced by IL-1beta in human synovial fibroblasts. Rheumatol Int 2010, 30(9):1197-1203.
Rasheed Z., Anbazhagan A.N., Akhtar N., Ramamurthy S., Voss F.R., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009, 11. R71.
Ahmed S., Wang N., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 2004, 308:767-773.
Haqqi T.M., Anthony D.D., Gupta S., Ahmad N., Lee M.S., Kumar G.K., et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A 1999, 96:4524-4529.
Dave M., Attur M., Palmer G., Al-Mussawir H.E., Kennish L., Patel J., et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008, 58:2786-2797.
Csaki C., Keshishzadeh N., Fischer K., Shakibaei M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 2008, 75:677-687.
Shakibaei M., Csaki C., Nebrich S., Mobasheri A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008, 76:1426-1439.
Lei M., Liu S.Q., Liu Y.L. Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1beta. Acta Pharmacol Sin 2008, 29:1350-1356.
Elmali N., Baysal O., Harma A., Esenkaya I., Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007, 30:1-6.
Elmali N., Esenkaya I., Harma A., Ertem K., Turkoz Y., Mizrak B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 2005, 54:158-162.
Garbacki N., Angenot L., Bassleer C., Damas J., Tits M. Effects of prodelphinidins isolated from Ribes nigrum on chondrocyte metabolism and COX activity. Naunyn Schmiedebergs Arch Pharmacol 2002, 365:434-441.
Sato M., Miyazaki T., Kambe F., Maeda K., Seo H. Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells. J Rheumatol 1997, 24:1680-1684.
Kang K., Hwang H.J., Hong D.H., Park Y., Kim S.H., Lee B.H., et al. Antioxidant and antiinflammatory activities of ventol, a phlorotannin-rich natural agent derived from Ecklonia cava, and its effect on proteoglycan degradation in cartilage explant culture. Res Commun Mol Pathol Pharmacol 2004, 115-116:77-95.
Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010, 79:330-338.
Biasutto L., Marotta E., Bradaschia A., Fallica M., Mattarei A., Garbisa S., et al. Soluble polyphenols: synthesis and bioavailability of 3,4′,5-tri(alpha-D-glucose-3-O-succinyl) resveratrol. Bioorg Med Chem Lett 2009, 19:6721-6724.
Li B., Chen F., Wang X., Ji B., Wu Y. Isolation and identification of antioxidative peptides from porcine collagen hydrolysate by consecutive chromatography and electrospray ionization-mass spectrometry. Food Chemistry 2007, 102:1135-1143.
Zhang Y., Kouguchi T., Shimizu M., Ohmori T., Takahata Y., Morimatsu F. chicken collagen hydrolysate protects rats from hypertension and cardiovascular damage. J Med Food 2010, 56(3):208-210.
Faria M., da Costa E.L., Gontijo J.A., Netto F.M. Evaluation of the hypotensive potential of bovine and porcine collagen hydrolysates. J Med Food 2008, 11:560-567.
Heinecke L.F., Grzanna M.W., Au A.Y., Mochal C.A., Rashmir-Raven A., Frondoza C.G. Inhibition of cyclooxygenase-2 expression and prostaglandin E2 production in chondrocytes by avocado soybean unsaponifiables and epigallocatechin gallate. Osteoarthritis Cartilage 2010, 18:220-227.
Csaki C., Mobasheri A., Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 2009, 11. R165.
Cobelens P.M., Heijnen C.J., Nieuwenhuis E.E., Kramer P.P., van der Zee R., van Eden W., et al. Treatment of adjuvant-induced arthritis by oral administration of mycobacterial Hsp65 during disease. Arthritis Rheum 2000, 43:2694-2702.
So J.S., Kwon H.K., Lee C.G., Yi H.J., Park J.A., Lim S.Y., et al. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 2008, 45:2690-2699.
So J.S., Lee C.G., Kwon H.K., Yi H.J., Chae C.S., Park J.A., et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 2008, 46:172-180.
Baharav E., Mor F., Halpern M., Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 2004, 134:1964-1969.
Hatakka K., Martio J., Korpela M., Herranen M., Poussa T., Laasanen T., et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. Scand J Rheumatol 2003, 32:211-215.